AIRLINK 74.39 Increased By ▲ 0.14 (0.19%)
BOP 5.04 Decreased By ▼ -0.01 (-0.2%)
CNERGY 4.55 Increased By ▲ 0.13 (2.94%)
DFML 37.38 Increased By ▲ 1.54 (4.3%)
DGKC 90.80 Increased By ▲ 2.80 (3.18%)
FCCL 22.51 Increased By ▲ 0.31 (1.4%)
FFBL 32.75 Increased By ▲ 0.03 (0.09%)
FFL 9.74 Decreased By ▼ -0.05 (-0.51%)
GGL 10.90 Increased By ▲ 0.10 (0.93%)
HBL 115.80 Decreased By ▼ -0.10 (-0.09%)
HUBC 136.30 Increased By ▲ 0.46 (0.34%)
HUMNL 10.13 Increased By ▲ 0.29 (2.95%)
KEL 4.60 Decreased By ▼ -0.01 (-0.22%)
KOSM 4.98 Increased By ▲ 0.32 (6.87%)
MLCF 40.25 Increased By ▲ 0.37 (0.93%)
OGDC 138.15 Increased By ▲ 0.25 (0.18%)
PAEL 27.39 Increased By ▲ 0.96 (3.63%)
PIAA 24.45 Decreased By ▼ -1.83 (-6.96%)
PIBTL 6.71 Decreased By ▼ -0.05 (-0.74%)
PPL 123.40 Increased By ▲ 0.50 (0.41%)
PRL 27.24 Increased By ▲ 0.55 (2.06%)
PTC 14.08 Increased By ▲ 0.08 (0.57%)
SEARL 59.40 Increased By ▲ 0.70 (1.19%)
SNGP 69.90 Decreased By ▼ -0.50 (-0.71%)
SSGC 10.38 Increased By ▲ 0.02 (0.19%)
TELE 8.65 Increased By ▲ 0.09 (1.05%)
TPLP 11.28 Decreased By ▼ -0.10 (-0.88%)
TRG 64.55 Increased By ▲ 0.32 (0.5%)
UNITY 26.70 Increased By ▲ 0.65 (2.5%)
WTL 1.40 Increased By ▲ 0.02 (1.45%)
BR100 7,864 Increased By 25.8 (0.33%)
BR30 25,594 Increased By 134 (0.53%)
KSE100 75,312 Increased By 381 (0.51%)
KSE30 24,200 Increased By 53.9 (0.22%)

NEW YORK: A Hawaii court ordered Bristol-Myers Squibb and Sanofi to pay the state $834 million over marketing claims for blood thinner, Plavix, according to news reports.

The two pharmaceutical giants said they intend to appeal the decision, which concluded that the companies engaged in unfair and deceptive business practices.

The state of Hawaii alleged the companies misled consumers about the benefit of using the drug, particularly for people of East Asian ancestry.

The drug makers “intend to appeal the trial court’s decision and we are confident in our success on appeal,” the companies said.

The state pointed to results showing the treatment did not work well for some patients of Asian or Pacific-island descent who could not properly metabolize the drug, according to the reports.

But the two companies disagreed, saying, “Leading cardiologists have examined the scientific evidence and continue to recommend Plavix as the standard of care for all its indications regardless of race or ethnicity.

Comments

Comments are closed.